PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

M T Dillon; Z Boylan; D Smith; J Guevara; K Mohammed; C Peckitt; M Saunders; U Banerji; G Clack; S A Smith; J F Spicer; M D Forster; K J Harrington

doi:10.1016/j.ctro.2018.06.001

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

Clin Transl Radiat Oncol. 2018 Jun 8:12:16-20. doi: 10.1016/j.ctro.2018.06.001. eCollection 2018 Aug.

Authors

M T Dillon^{1

2}, Z Boylan³, D Smith², J Guevara², K Mohammed², C Peckitt², M Saunders⁴, U Banerji², G Clack⁵, S A Smith⁶, J F Spicer⁷, M D Forster⁸, K J Harrington^{1

2}

Affiliations

¹ The Institute of Cancer Research, London, UK.
² The Royal Marsden NHS Foundation Trust, London, UK.
³ Cancer Research UK, London, UK.
⁴ The Christie NHS Foundation Trust, UK.
⁵ Department of Oncology and Metabolism, University of Sheffield Medical School, Beech Hill Road, SHEFFIELD S10 2RX, UK.
⁶ AstraZeneca, Cambridge, UK.
⁷ Kings College London, UK.
⁸ University College London Hospitals NHS Foundation Trust and UCL Cancer Centre, London UK.

Abstract

PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.

Keywords: ATR inhibition; Clinical trial; DNA damage response; Phase I; Radiosensitization.

Abstract

Grants and funding